Capricor Therapeutics (CAPR) director boosts stake via 3,937-share option exercise

Rhea-AI Filing Summary

Capricor Therapeutics director Frank Litvack reported a routine option exercise. He exercised stock options covering 3,937 shares of Common Stock at $1.39 per share, converting a derivative position into direct share ownership. Following the exercise, he holds 133,776 Common shares directly and 46,278 Common shares indirectly through the Litvack Curtis Family Trust, where he serves as trustee. The exercised option grant, originally issued in 2016, had been adjusted for a 1-for-10 reverse stock split in 2019 and a share reprice in 2020. No open-market purchases or sales were reported in this filing.

Insights

Equity compensation analyst

Routine option exercise increases the director’s direct share holdings.

Director Frank Litvack exercised stock options to acquire 3,937 Capricor Therapeutics shares at an exercise price of $1.39 per share. This converts a derivative award from 2016 into common stock without any reported market sale.

The related stock option position is now fully exercised, as the derivative balance after the transaction is shown as zero. He now holds 133,776 shares directly and 46,278 shares indirectly via a family trust, indicating a meaningful continuing equity stake.

No open-market buying or selling was disclosed, so the filing mainly updates ownership structure rather than signaling a change in sentiment. Future company filings may provide additional context on any subsequent transactions or new equity awards.

Insider Trade Summary

3,937 shares exercised/converted

Mixed 3 txns

Insider Litvack Frank

Role null

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,937	$0.00	--
Exercise	Common Stock	3,937	$1.39	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 133,776 shares (Direct, null); Common Stock — 46,278 shares (Indirect, Held in Family Trust)

Footnotes (1)

1. Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee. This option was granted on June 2, 2016 and was previously reported as covering 39,375 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. 1,750 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.

Key Figures

Options exercised: 3,937 shares Exercise price: $1.39 per share Direct holdings after transaction: 133,776 shares +3 more

6 metrics

Options exercised 3,937 shares Common Stock acquired via option exercise on May 13, 2026

Exercise price $1.39 per share Exercise or conversion price for stock option

Direct holdings after transaction 133,776 shares Common Stock directly owned after exercise

Indirect trust holdings 46,278 shares Common Stock held by Litvack Curtis Family Trust

Original option grant size 39,375 shares Grant on June 2, 2016 before reverse split adjustment

Original option exercise price $3.12 per share Pre-adjustment exercise price before reprice to $1.39

Key Terms

Stock Option (Right to Buy), reverse stock split, share reprice, Family Trust

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

reverse stock split financial

"reflect a 1-for-10 reverse stock split that occurred on June 4, 2019"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

share reprice financial

"and a share reprice of $1.39 per share that occurred on February 12, 2020"

Family Trust financial

"Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Litvack Frank

(Last) (First) (Middle)

C/O CAPRICOR THERAPEUTICS, INC.

10865 ROAD TO THE CURE, SUITE 150

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CAPRICOR THERAPEUTICS, INC. [ CAPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		M		3,937	A	$1.39	133,776	D
Common Stock								46,278	I	Held in Family Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.39(2)	05/13/2026		M			3,937	(3)	06/02/2026	Common Stock	3,937	$0	0	D

Explanation of Responses:

1. Held by Litvack Curtis Family Trust for which the Reporting Person serves as trustee.

2. This option was granted on June 2, 2016 and was previously reported as covering 39,375 shares at an exercise price of $3.12 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.

3. 1,750 shares vested immediately on June 2, 2016. The remaining shares vested on December 31, 2016.

	/s/ Linda Marban, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CAPR director Frank Litvack report?

Frank Litvack reported exercising stock options to acquire 3,937 shares of Capricor Therapeutics common stock at $1.39 per share. This was a derivative exercise, not an open-market purchase or sale, and increased his direct share ownership in the company.

At what price did Frank Litvack exercise his Capricor (CAPR) stock options?

He exercised his Capricor stock options at an exercise price of $1.39 per share for 3,937 underlying common shares. This converted a previously granted option award into common stock without reporting any related open-market sale in the same filing.

How many Capricor Therapeutics shares does Frank Litvack hold after this Form 4?

After the reported transactions, Frank Litvack holds 133,776 Capricor Therapeutics common shares directly. He also has indirect ownership of 46,278 common shares through the Litvack Curtis Family Trust, where he serves as trustee, reflecting combined direct and indirect positions.

Did Frank Litvack sell any Capricor (CAPR) shares in this Form 4 filing?

No, the Form 4 does not show any open-market sales of Capricor shares by Frank Litvack. It reports an option exercise to acquire 3,937 common shares and an indirect holding entry for family trust shares, without any sale transaction codes or sale prices disclosed.

What is the role of the Litvack Curtis Family Trust in CAPR share ownership?

The Litvack Curtis Family Trust holds 46,278 Capricor common shares, with Frank Litvack serving as trustee. This means those shares are reported as indirect ownership. The Form 4 clarifies that the trust, not Litvack personally, is the holder of that indirect position.

What is the background of the Capricor option grant exercised by Frank Litvack?

The exercised option was granted on June 2, 2016 and initially covered 39,375 shares at $3.12. It was adjusted for a 1-for-10 reverse stock split in June 2019 and later repriced to $1.39 per share in February 2020 before Litvack exercised 3,937 shares.